Both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) have individually been shown to reduce cardiovascular and kidney outcomes in patients with T2DM, with a low hypoglycemia risk [3, 4]
Laboratory protocols explore how senescent T cells, B cells, and other immune cells contribute to age-related immune dysfunction, while FOXO4-DRI administration provides researchers with methods for testing immune system restoration following senescent cell elimination
10.1002/med.20142 21 MohsinS.BaniyasM
Purity: 98% (awaiting COA)
Eli Lilly ran two Phase III studies of people living with obesity and moderate-to-severe obstructive sleep apnea for 52 weeks each
FDA Commissioner Makary publicly endorsed the deal, and the resolution may serve as a template for how other telehealth companies navigate the evolving regulatory landscape